Liangmin Fu
Overview
Explore the profile of Liangmin Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pan Y, Liu S, Shu G, Chen M, Fu L, Chen C, et al.
Cell Death Dis
. 2025 Feb;
16(1):125.
PMID: 39988631
Axitinib resistance remains a serious challenge in the treatment of advanced renal cell carcinoma (RCC), and the underlying mechanisms are not fully understood. Here, we constructed an in vivo axitinib-resistant...
2.
Yu A, Fu L, Jing L, Wang Y, Ma Z, Zhou X, et al.
Cell Death Differ
. 2024 Dec;
PMID: 39672819
The impact of amino acids on tumor immunotherapy is gradually being uncovered. In this study, we screened various essential and non-essential amino acids and found that methionine enhances mRNA methylation...
3.
Zhou T, Chen Y, Fu L, Wang S, Ding H, Bai Q, et al.
Regen Biomater
. 2024 Sep;
11:rbae107.
PMID: 39246578
Owing to the unpredictable size of wounds and irregular edges formed by trauma, nanofibers' highly customizable and adherent deposition can contribute to intervention in the healing process. However, electrospinning is...
4.
Lin H, Fu L, Zhou X, Yu A, Chen Y, Liao W, et al.
Cancer Lett
. 2024 Mar;
593:216807.
PMID: 38462037
The tumour microenvironment (TME) drives bladder cancer (BLCA) progression. Targeting the TME has emerged as a promising strategy for BLCA treatment in recent years. Furthermore, checkpoint blockade therapies are only...
5.
Yan Q, Huang S, Fu L, Dai T
Asian J Surg
. 2024 Mar;
47(6):2965-2966.
PMID: 38433081
No abstract available.
6.
Xu B, Li M, Weng N, Zhou C, Chen Y, Wei J, et al.
Biomedicines
. 2024 Feb;
12(2).
PMID: 38397869
Disulfidoptosis, a novel form of cell death, is distinct from other well-known cell death mechanisms. Consequently, a profound investigation into disulfidoptosis elucidates the fundamental mechanisms underlying tumorigenesis, presenting promising avenues...
7.
PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma
Shu G, Chen M, Liao W, Fu L, Lin M, Gui C, et al.
Cancer Res
. 2024 Feb;
84(10):1659-1679.
PMID: 38382068
Significance: PABPC1L functions as a key factor in renal cell carcinoma immune evasion, enhancing IDO1 and impeding T-cell function, and represents a potential target to enhance the efficacy of immune...
8.
Xu B, Liang J, Fu L, Wei J, Lin J
Curr Cancer Drug Targets
. 2024 Feb;
24(8):846-866.
PMID: 38303526
Background: The protein Solute Carrier Family 7 Member 11 (SLC7A11) plays a pivotal role in cellular redox homeostasis by suppressing disulfidptosis, which restricts tumor growth. Yet, its relevance in prognosis,...
9.
Wang W, Huang G, Lin H, Ren L, Fu L, Mao X
Front Oncol
. 2024 Jan;
13:1216134.
PMID: 38264752
[This corrects the article DOI: 10.3389/fonc.2022.1102392.].
10.
Yu A, Hu J, Fu L, Huang G, Deng D, Zhang M, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37802603
Background: Immune checkpoint inhibitor (ICI) therapy improves the survival of patients with advanced bladder cancer (BLCA); however, its overall effectiveness is limited, and many patients still develop immunotherapy resistance. The...